Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates: A Randomized...

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Millions of patients rely on vitamin K antagonists (VKAs) for anticoagulation.
• Urgent surgical procedures in VKA patients necessitate rapid reversal to mitigate bleeding risks.
• Effective and safe VKA reversal agents are crucial for perioperative management.

Purpose of the Study:

• To assess the hemostatic noninferiority of an investigational 4-factor prothrombin complex concentrate (4F-PCC) versus a control 4F-PCC.
• To evaluate the efficacy of rapid VKA reversal in patients requiring urgent surgery.
• To compare the safety profiles of the investigational and control 4F-PCCs.

Main Methods:

• A phase 3, double-blind, noninferiority randomized clinical trial (LEX-209) involving 208 adult patients.
• Participants were randomized 1:1 to receive either investigational or control 4F-PCC via single intravenous infusion.
• Hemostatic efficacy was assessed by an independent adjudication board using a 4-point scale at the end of surgery.

Main Results:

• The investigational 4F-PCC achieved noninferior hemostatic efficacy compared to the control 4F-PCC (94.3% vs 94.2%), meeting the prespecified noninferiority margin.
• Effective hemostasis was achieved in the vast majority of patients in both groups.
• The incidence of thrombotic events and mortality was comparable to expected rates for 4F-PCC use, with similar safety profiles observed.

Conclusions:

• The investigational 4F-PCC is hemostatically noninferior to the control 4F-PCC for rapid VKA reversal in patients undergoing urgent surgery.
• The safety profiles of both 4F-PCCs were similar, indicating comparable tolerability.
• These findings support the investigational 4F-PCC as a valuable therapeutic option for surgical patients requiring urgent VKA reversal.